GLP-1/GIP/glucagon receptor (triple)
Assets acting on this target.
- Class
- Triple GLP-1/GIP/glucagon receptor agonist
This mechanism targets three related receptors (for GLP-1, GIP, and glucagon) that together govern how the body manages blood sugar, appetite, and energy use. GLP-1 and GIP are gut hormones released after eating that signal the pancreas to release insulin and that also reduce appetite and slow stomach emptying. Glucagon, in contrast, is best known for raising blood sugar by signaling the liver to release stored glucose, but it also increases the rate at which the body burns energy. A single molecule engineered to activate all three receptors combines the appetite-suppressing and insulin-supporting effects of GLP-1 and GIP with the energy-expenditure-boosting effect of glucagon, aiming for greater reductions in body weight and improved metabolic markers than agents that engage only one or two of these pathways. This combined approach is being explored primarily for obesity, type 2 diabetes, and metabolic liver disease, conditions in which excess weight, insulin resistance, and abnormal fat storage are interconnected. The rationale for pursuing all three receptors together, rather than one alone, is that each contributes a distinct and complementary physiological effect on appetite, insulin release, and metabolic rate.
Related mechanisms
GLP-1/GIP/glucagon receptor (triple) drugs compared
5 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| retatrutide | Eli Lilly | peptide | Phase 3 | Phase 3 in Atherosclerotic Cardiovascular Disease; Phase 3 in Chronic Kidney Disease; Phase 3 in Obesity; Phase 3 in Type 2 Diabetes |
| UBT251 | Novo Nordisk, United Bio-Technology (Hengqin) | peptide | Phase 3 | Phase 3 in Obesity; Phase 3 in Type 2 Diabetes; Phase 2 in Chronic Kidney Disease |
| Efocipegtrutide | Hanmi Pharmaceutical | peptide | Phase 2 | Phase 2 in MASH / NASH; Phase 1 in Obesity |
| HM15275 | Hanmi Pharmaceutical | peptide | Phase 2 | Phase 2 in Obesity; Phase 2 in Type 2 Diabetes |
| HRS-4729 | Jiangsu Hengrui Pharmaceuticals, Kailera Therapeutics | peptide | Phase 2 | Phase 2 in Obesity |